[Skip to Navigation]
February 1979

Timolol Plus Maximum-Tolerated Antiglaucoma Therapy

Author Affiliations

From the Glaucoma Center, Department of Ophthalmology, Washington University School of Medicine, St Louis. Dr Zimmerman is now with Louisiana State University School of Medicine, New Orleans, and Dr Yablonski is with Mount Sinai School of Medicine, New York.

Arch Ophthalmol. 1979;97(2):278-279. doi:10.1001/archopht.1979.01020010130005

• Eighteen patients with glaucoma with a mean intraocular pressure (IOP) ± SD of 28.7 ± 5.5 mm Hg who were receiving maximum-tolerated antiglaucoma therapy were given 0.5% timolol maleate or a placebo twice daily to one eye in a double-masked cross-over fashion in addition to their usual antiglaucoma drugs. After one week of timolol therapy, the mean IOP was significantly lower (23.1 ± 4.1 mm Hg) than after one week of placebo administration (26.4 ± 7.8 mm Hg; P < .025, paired t test). Five patients had decreases in IOP >4 mm Hg, while six patients reached IOPs < 21 mm Hg while receiving timolol therapy. No adverse reactions to timolol were noted. Timolol had an additional IOP-lowering effect in some patients receiving maximum-tolerated medical therapy.

Add or change institution